Compare ROAD & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ROAD | GKOS |
|---|---|---|
| Founded | 2001 | 1998 |
| Country | United States | United States |
| Employees | N/A | 995 |
| Industry | Engineering & Construction | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.3B |
| IPO Year | 2018 | 2015 |
| Metric | ROAD | GKOS |
|---|---|---|
| Price | $115.30 | $109.49 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | $123.50 | ★ $127.71 |
| AVG Volume (30 Days) | 480.9K | ★ 594.8K |
| Earning Date | 02-05-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | N/A |
| EPS | ★ 1.84 | N/A |
| Revenue | ★ $2,812,356,000.00 | $469,820,000.00 |
| Revenue This Year | $25.23 | $31.15 |
| Revenue Next Year | $10.22 | $24.15 |
| P/E Ratio | $63.64 | ★ N/A |
| Revenue Growth | ★ 54.20 | 30.38 |
| 52 Week Low | $64.79 | $73.16 |
| 52 Week High | $138.90 | $163.71 |
| Indicator | ROAD | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 48.46 |
| Support Level | $106.61 | $109.07 |
| Resistance Level | $116.21 | $115.00 |
| Average True Range (ATR) | 4.19 | 2.70 |
| MACD | 0.49 | -1.17 |
| Stochastic Oscillator | 72.98 | 12.13 |
Construction Partners Inc operates as a civil infrastructure company. It specializes in the construction and maintenance of roadways. The company through its subsidiaries, provides various products and services to both public and private infrastructure projects, with an emphasis on highways, roads, bridges, airports, and commercial and residential developments. Its operations consist of manufacturing and distributing hot mix asphalt, paving activities, including the construction of roadway base layers and application of asphalt pavement, site development, including the installation of utility and drainage systems, and others. The company has a single segment which predominantly consists of infrastructure and road construction, and operates across various states in the United States.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.